METHOD OF TREATING BREAST CANCER USING A COMBINATION OF VITAMIN D ANALOGUES AND OTHER AGENTS

• US 20060003021A1
• Filed: 06/30/2004
• Published: 01/05/2006
• Est. Priority Date: 06/30/2004
• Status: Active Grant

• Current Assignee: Bone Care International LLC
• Original Assignee: Bone Care International LLC
• Inventors: Strugnell, Stephen A., Wigington, Don
• Granted Patent: US 7,094,775 B2
• Time in Patent Office: Days
• US Class Current: 424/649
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/138 Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377
• CPC Class Codes: A61K 31/255 of sulfoxy acids or sulfur analogues thereof
• CPC Class Codes: A61K 31/282 Platinum compounds
• CPC Class Codes: A61K 31/337 having four-membered rings, e.g. taxol
• CPC Class Codes: A61K 31/513 having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• CPC Class Codes: A61K 31/555 containing heavy metals, e.g. hemin, hematin, melarsoprol
• CPC Class Codes: A61K 31/592 9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
• CPC Class Codes: A61K 31/70 Carbohydrates; Sugars; Derivatives thereof sorbitol A61K31/047
• CPC Class Codes: A61K 31/704 attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin digitoxin A61K31/7048
• CPC Class Codes: A61P 35/00 Antineoplastic agents

Abstract

The invention provides therapeutic methods for inhibiting, ameliorating or alleviating the hyperproliferative cellular activity of diseases of the breast, e.g., breast cancer, which includes administering to a patient in need thereof an active vitamin D analogue and another anticancer agent. Cell differentiation is promoted, induced or enhanced without causing to the patient dose-limiting hypercalcemia and hypercalciuria.

Claims

1. A method of synergistically inhibiting the growth of human breast cancer cells, comprising contacting the cells with a first composition which comprises 1α

,24-dihydroxyvitamin D₂ and a second composition which comprises an agent selected from the group consisting of doxorubicin, cisplatin and paclitaxel or combinations thereof.

2. The method of claim 1 wherein the agent is doxorubicin.

3. The method of claim 1 wherein the agent is cisplatin.

4. The method of claim 1 wherein the agent is paclitaxel.

5. The method of claim 1, wherein the first and second compositions are administered to a human cancer patient.

6. The method of claim 5 wherein the first and second compositions are co-administered.

7. The method of claim 5 wherein the first and second compositions are administered in a daily regimen.

8. The method of claim 5 wherein the first and second compositions are administered in an episodic regimen.

9. The method of claim 5 wherein the first composition is administered intravenously.

10. The method of claim 5 wherein the first composition is administered orally.

11. The method of claim 5 wherein the first composition is administered in an amount of 0.01 μ

g to 400 μ

g of 1α

,24-dihydroxyvitamin D₂.

12-28. -28. (canceled)